Trials / Terminated
TerminatedNCT03519256
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| BIOLOGICAL | BCG | Specified dose on specified days |
| DRUG | BMS-986205 | Specified dose on specified days |
Timeline
- Start date
- 2018-08-02
- Primary completion
- 2022-08-22
- Completion
- 2022-08-24
- First posted
- 2018-05-08
- Last updated
- 2023-06-01
- Results posted
- 2023-06-01
Locations
88 sites across 15 countries: United States, Argentina, Australia, Brazil, Canada, Chile, China, France, Hong Kong, Italy, Mexico, Netherlands, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03519256. Inclusion in this directory is not an endorsement.